Top

Published in:

01-05-2016

The expanding landscape of diffusion-weighted MRI in prostate cancer

Authors: Andreas G. Wibmer, Evis Sala, Hedvig Hricak, Hebert Alberto Vargas

Published in: Abdominal Radiology | Issue 5/2016

Abstract

The added value of diffusion-weighted magnetic resonance imaging (DW-MRI) for the detection, localization, and staging of primary prostate cancer has been extensively reported in original studies and meta-analyses. More recently, DW-MRI and related techniques have been used to noninvasively assess prostate cancer aggressiveness and estimate its biological behavior. The present article aims to summarize the potential applications of DW-MRI for noninvasive optimization of pretherapeutic risk assessment, patient management decisions, and evaluation of treatment response.

Barentsz JO, Richenberg J, Clements R, et al. (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22(4):746–757CrossRefPubMedPubMedCentral

Eberhardt SC, Carter S, Casalino DD, et al. (2013) ACR appropriateness criteria prostate cancer–pretreatment detection, staging, and surveillance. J Am Coll Radiol 10(2):83–92CrossRefPubMed

Tan CH, Wei W, Johnson V, Kundra V (2012) Diffusion-weighted MRI in the detection of prostate cancer: meta-analysis. AJR Am J Roentgenol 199(4):822–829CrossRefPubMedPubMedCentral

Jie C, Rongbo L, Ping T (2014) The value of diffusion-weighted imaging in the detection of prostate cancer: a meta-analysis. Eur Radiol 24(8):1929–1941CrossRefPubMedPubMedCentral

Wu LM, Xu JR, Ye YQ, Lu Q, Hu JN (2012) The clinical value of diffusion-weighted imaging in combination with T2-weighted imaging in diagnosing prostate carcinoma: a systematic review and meta-analysis. AJR Am J Roentgenol 199(1):103–110CrossRefPubMed

Tan CH, Hobbs BP, Wei W, Kundra V (2015) Dynamic contrast-enhanced MRI for the detection of prostate cancer: meta-analysis. AJR Am J Roentgenol 204(4):W439–W448CrossRefPubMed

Medved M, Soylu-Boy FN, Karademir I, et al. (2014) High-resolution diffusion-weighted imaging of the prostate. AJR Am J Roentgenol 203(1):85–90CrossRefPubMed

Nguyen C, Sharif-Afshar AR, Fan Z, et al. (2015) 3D high-resolution diffusion-weighted MRI at 3T: preliminary application in prostate cancer patients undergoing active surveillance protocol for low-risk prostate cancer. Magn Reson Med 11(10):25609

Jahn JL, Giovannucci EL, Stampfer MJ (2015) The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the prostate-specific Antigen-era. Int J Cancer 137(12):2795–2802CrossRefPubMed

10.

NCI (2015) Surveillance, epidemiology, and end results program. http://seer.cancer.gov/statfacts/html/prost.html. Accessed 01 June 2015

11.

Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 29(9):1228–1242CrossRefPubMed

12.

Pierorazio PM, Walsh PC, Partin AW, Epstein JI (2013) Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 111(5):753–760CrossRefPubMedPubMedCentral

13.

Cohen MS, Hanley RS, Kurteva T, et al. (2008) Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis. Eur Urol 54(2):371–381CrossRefPubMed

14.

Itou Y, Nakanishi K, Narumi Y, Nishizawa Y, Tsukuma H (2011) Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the aggressiveness of prostate cancer? J Magn Reson Imaging 33(1):167–172CrossRefPubMed

15.

Verma S, Rajesh A, Morales H, et al. (2011) Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. AJR Am J Roentgenol 196(2):374–381CrossRefPubMed

16.

Hambrock T, Somford DM, Huisman HJ, et al. (2011) Relationship between apparent diffusion coefficients at 3.0-T MR imaging and gleason grade in peripheral zone prostate cancer. Radiology 259(2):453–461CrossRefPubMed

17.

Vargas HA, Akin O, Franiel T, et al. (2011) Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 259(3):775–784CrossRefPubMedPubMedCentral

18.

Bittencourt LK, Barentsz JO, de Miranda LC, Gasparetto EL (2012) Prostate MRI: diffusion-weighted imaging at 1.5T correlates better with prostatectomy Gleason Grades than TRUS-guided biopsies in peripheral zone tumours. Eur Radiol 22(2):468–475CrossRefPubMed

19.

Oto A, Yang C, Kayhan A, et al. (2011) Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol 197(6):1382–1390CrossRefPubMed

20.

Jung SI, Donati OF, Vargas HA, et al. (2013) Transition zone prostate cancer: incremental value of diffusion-weighted endorectal MR imaging in tumor detection and assessment of aggressiveness. Radiology 269(2):493–503CrossRefPubMed

21.

Somford DM, Hambrock T, Hulsbergen-van de Kaa CA, et al. (2012) Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score ≤ = 3 + 3 = 6 upon schematic TRUS-guided biopsy: a radical prostatectomy correlated series. Invest Radiol 47(3):153–158PubMed

22.

Donati OF, Mazaheri Y, Afaq A, et al. (2014) Prostate cancer aggressiveness: assessment with whole-lesion histogram analysis of the apparent diffusion coefficient. Radiology 271(1):143–152CrossRefPubMed

23.

Peng Y, Jiang Y, Antic T, et al. (2014) Validation of quantitative analysis of multiparametric prostate MR images for prostate cancer detection and aggressiveness assessment: a cross-imager study. Radiology 271(2):461–471CrossRefPubMed

24.

Borren A, Moman MR, Groenendaal G, et al. (2013) Why prostate tumour delineation based on apparent diffusion coefficient is challenging: an exploration of the tissue microanatomy. Acta Oncol 52(8):1629–1636CrossRefPubMed

25.

Gibbs P, Liney GP, Pickles MD, et al. (2009) Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Invest Radiol 44(9):572–576CrossRefPubMed

26.

Bae H, Yoshida S, Matsuoka Y, et al. (2014) Apparent diffusion coefficient value as a biomarker reflecting morphological and biological features of prostate cancer. Int Urol Nephrol 46(3):555–561CrossRefPubMed

27.

Sadinski M, Medved M, Karademir I, et al. (2015) Short-term reproducibility of apparent diffusion coefficient estimated from diffusion-weighted MRI of the prostate. Abdom Imaging 25:25

28.

Peng Y, Jiang Y, Antic T, et al. (2014) Apparent diffusion coefficient for prostate cancer imaging: impact of B values. AJR Am J Roentgenol 202(3):W247–W253CrossRefPubMed

29.

Thormer G, Otto J, Reiss-Zimmermann M, et al. (2012) Diagnostic value of ADC in patients with prostate cancer: influence of the choice of b values. Eur Radiol 22(8):1820–1828CrossRefPubMed

30.

Mazaheri Y, Vargas HA, Nyman G, et al. (2013) Diffusion-weighted MRI of the prostate at 3.0 T: comparison of endorectal coil (ERC) MRI and phased-array coil (PAC) MRI-The impact of SNR on ADC measurement. Eur J Radiol 82(10):e515–e520CrossRefPubMed

31.

Wibmer A, Hricak H, Gondo T, et al. (2015) Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores. Eur Radiol 21:21

32.

Rosenkrantz AB, Triolo MJ, Melamed J, et al. (2015) Whole-lesion apparent diffusion coefficient metrics as a marker of percentage Gleason 4 component within Gleason 7 prostate cancer at radical prostatectomy. J Magn Reson Imaging 41(3):708–714CrossRefPubMedPubMedCentral

33.

Vargas HA, Lawrence EM, Mazaheri Y, Sala E (2015) Updates in advanced diffusion-weighted magnetic resonance imaging techniques in the evaluation of prostate cancer. World J Radiol 7(8):184–188CrossRefPubMedPubMedCentral

34.

Dopfert J, Lemke A, Weidner A, Schad LR (2011) Investigation of prostate cancer using diffusion-weighted intravoxel incoherent motion imaging. Magn Reson Imaging 29(8):1053–1058. doi:10.1016/j.mri.2011.06.001 CrossRefPubMed

35.

Shinmoto H, Tamura C, Soga S, et al. (2012) An intravoxel incoherent motion diffusion-weighted imaging study of prostate cancer. AJR Am J Roentgenol 199(4):W496–W500. doi:10.2214/ajr.11.8347 CrossRefPubMed

36.

Zhang YD, Wang Q, Wu CJ, et al. (2015) The histogram analysis of diffusion-weighted intravoxel incoherent motion (IVIM) imaging for differentiating the gleason grade of prostate cancer. Eur Radiol 25(4):994–1004CrossRefPubMed

37.

Steven AJ, Zhuo J, Melhem ER (2014) Diffusion kurtosis imaging: an emerging technique for evaluating the microstructural environment of the brain. AJR Am J Roentgenol 202(1):W26–W33CrossRefPubMed

38.

Quentin M, Pentang G, Schimmoller L, et al. (2014) Feasibility of diffusional kurtosis tensor imaging in prostate MRI for the assessment of prostate cancer: preliminary results. Magn Reson Imaging 32(7):880–885. doi:10.1016/j.mri.2014.04.005 CrossRefPubMed

39.

Rosenkrantz AB, Sigmund EE, Johnson G, et al. (2012) Prostate cancer: feasibility and preliminary experience of a diffusional kurtosis model for detection and assessment of aggressiveness of peripheral zone cancer. Radiology 264(1):126–135. doi:10.1148/radiol.12112290 CrossRefPubMed

40.

Suo S, Chen X, Wu L, et al. (2014) Non-Gaussian water diffusion kurtosis imaging of prostate cancer. Magn Reson Imaging 32(5):421–427. doi:10.1016/j.mri.2014.01.015 CrossRefPubMed

41.

Wang Q, Li H, Yan X, et al. (2015) Histogram analysis of diffusion kurtosis magnetic resonance imaging in differentiation of pathologic Gleason grade of prostate cancer. Urol Oncol 33(8):337 e315–337 e324CrossRef

42.

Li C, Chen M, Li S, et al. (2014) Detection of prostate cancer in peripheral zone: comparison of MR diffusion tensor imaging, quantitative dynamic contrast-enhanced MRI, and the two techniques combined at 3.0 T. Acta Radiol 55(2):239–247. doi:10.1177/0284185113494978 CrossRefPubMed

43.

Roethke MC, Kuder TA, Kuru TH, et al. (2015) Evaluation of diffusion kurtosis imaging versus standard diffusion imaging for detection and grading of peripheral zone prostate cancer. Invest Radiol 50(8):483–489CrossRefPubMed

44.

Rosenkrantz AB, Padhani AR, Chenevert TL, et al. (2015) Body diffusion kurtosis imaging: basic principles, applications, and considerations for clinical practice. J Magn Reson Imaging 42(5):1190–1202CrossRefPubMed

45.

Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, et al. (2012) Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol 61(1):177–184CrossRefPubMed

46.

Zhang J, Xiu J, Dong Y, et al. (2014) Magnetic resonance imaging directed biopsy improves the prediction of prostate cancer aggressiveness compared with a 12-core transrectal ultrasound guided prostate biopsy. Mol Med Rep 9(5):1989–1997PubMed

47.

Somford DM, Hoeks CM, Hulsbergen-van de Kaa CA, et al. (2013) Evaluation of diffusion-weighted MR imaging at inclusion in an active surveillance protocol for low-risk prostate cancer. Invest Radiol 48(3):152–157CrossRefPubMed

48.

Mitsuzuka K, Koga H, Sugimoto M, et al. (2015) Current use of active surveillance for localized prostate cancer: a nationwide survey in Japan. Int J Urol 10(10):12813

49.

Preston MA, Feldman AS, Coen JJ, et al. (2015) Active surveillance for low-risk prostate cancer: need for intervention and survival at 10 years. Urol Oncol 6(15):00194–00195

50.

van As NJ, de Souza NM, Riches SF, et al. (2009) A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Urol 56(6):981–987CrossRefPubMed

51.

Giles SL, Morgan VA, Riches SF, et al. (2011) Apparent diffusion coefficient as a predictive biomarker of prostate cancer progression: value of fast and slow diffusion components. AJR Am J Roentgenol 196(3):586–591CrossRefPubMed

52.

Flavell RR, Westphalen AC, Liang C, et al. (2014) Abnormal findings on multiparametric prostate magnetic resonance imaging predict subsequent biopsy upgrade in patients with low risk prostate cancer managed with active surveillance. Abdom Imaging 39(5):1027–1035CrossRefPubMedPubMedCentral

53.

Jeong CW, Park YH, Hwang SI, et al. (2014) The role of 3-tesla diffusion-weighted magnetic resonance imaging in selecting prostate cancer patients for active surveillance. Prostate Int 2(4):169–175CrossRefPubMedPubMedCentral

54.

Morgan VA, Riches SF, Thomas K, et al. (2011) Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance. Br J Radiol 84(997):31–37CrossRefPubMedPubMedCentral

55.

Lee DH, Koo KC, Lee SH, et al. (2013) Tumor lesion diameter on diffusion weighted magnetic resonance imaging could help predict insignificant prostate cancer in patients eligible for active surveillance: preliminary analysis. J Urol 190(4):1213–1217CrossRefPubMed

56.

Rosenkrantz AB, Prabhu V, Sigmund EE, et al. (2013) Utility of diffusional kurtosis imaging as a marker of adverse pathologic outcomes among prostate cancer active surveillance candidates undergoing radical prostatectomy. AJR Am J Roentgenol 201(4):840–846CrossRefPubMed

57.

Park SY, Kim CK, Park BK, Lee HM, Lee KS (2011) Prediction of biochemical recurrence following radical prostatectomy in men with prostate cancer by diffusion-weighted magnetic resonance imaging: initial results. Eur Radiol 21(5):1111–1118CrossRefPubMed

58.

Matsuoka Y, Numao N, Saito K, et al. (2014) Candidate selection for quadrant-based focal ablation through a combination of diffusion-weighted magnetic resonance imaging and prostate biopsy. BJU Int 14(10):12901

59.

Cornud F, Khoury G, Bouazza N, et al. (2014) Tumor target volume for focal therapy of prostate cancer-does multiparametric magnetic resonance imaging allow for a reliable estimation? J Urol 191(5):1272–1279CrossRefPubMed

60.

Nemoto K, Tateishi T, Ishidate T (2010) Changes in diffusion-weighted images for visualizing prostate cancer during antiandrogen therapy: preliminary results. Urol Int 85(4):421–426CrossRefPubMed

61.

Kim AY, Kim CK, Park SY, Park BK (2014) Diffusion-weighted imaging to evaluate for changes from androgen deprivation therapy in prostate cancer. AJR Am J Roentgenol 203(6):W645–W650CrossRefPubMed

62.

Hotker AM, Mazaheri Y, Zheng J, et al. (2015) Prostate Cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI. Eur Radiol 29:29

63.

Reischauer C, Froehlich JM, Koh DM, et al. (2010) Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps-initial observations. Radiology 257(2):523–531CrossRefPubMed

64.

Eisenhauer EA, Therasse P, Bogaerts J, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247CrossRefPubMed

65.

Baker LC, Boult JK, Walker-Samuel S, et al. (2012) The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function. Br J Cancer 106(10):1638–1647CrossRefPubMedPubMedCentral

66.

Wang H, Fei B (2010) Diffusion-weighted MRI for monitoring tumor response to photodynamic therapy. J Magn Reson Imaging 32(2):409–417CrossRefPubMedPubMedCentral

67.

Graham TJ, Box G, Tunariu N, et al. (2014) Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. J Natl Cancer Inst 106(4):dju033CrossRefPubMed

68.

Blackledge MD, Collins DJ, Tunariu N, et al. (2014) Assessment of treatment response by total tumor volume and global apparent diffusion coefficient using diffusion-weighted MRI in patients with metastatic bone disease: a feasibility study. PLoS One 9(4):e91779CrossRefPubMedPubMedCentral

69.

Park SY, Kim CK, Park BK, et al. (2012) Early changes in apparent diffusion coefficient from diffusion-weighted MR imaging during radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 83(2):749–755CrossRefPubMed

70.

Decker G, Murtz P, Gieseke J, et al. (2014) Intensity-modulated radiotherapy of the prostate: dynamic ADC monitoring by DWI at 3.0 T. Radiother Oncol 113(1):115–120CrossRefPubMed

71.

Song I, Kim CK, Park BK, Park W (2010) Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T. AJR Am J Roentgenol 194(6):W477–W482CrossRefPubMed

72.

Liu L, Wu N, Ouyang H, Dai JR, Wang WH (2014) Diffusion-weighted MRI in early assessment of tumour response to radiotherapy in high-risk prostate cancer. Br J Radiol 87(1043):20140359CrossRefPubMedPubMedCentral

73.

Viswanath S, Toth R, Rusu M, et al. (2013) Quantitative evaluation of treatment related changes on multi-parametric MRI after laser interstitial thermal therapy of prostate cancer. Proc SPIE Int Soc Opt Eng 8671:86711FPubMedPubMedCentral

Title: The expanding landscape of diffusion-weighted MRI in prostate cancer
Authors: Andreas G. Wibmer
Evis Sala
Hedvig Hricak
Hebert Alberto Vargas
Publication date: 01-05-2016
Publisher: Springer US
Published in: Abdominal Radiology / Issue 5/2016
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-016-0646-6

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2016

Evaluation of the impact of computed high b-value diffusion-weighted imaging on prostate cancer detection

DCE MRI of prostate cancer

Commentary regarding the inter-reader reproducibility of PI-RADS version 2

Inverted V sign

The “Sausage” pancreas

Benign causes of diffusion restriction foci in the peripheral zone of the prostate: diagnosis and differential diagnosis

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage